| Bioactivity | Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that can selectively neutralize TGFβ1[1]. |
| Target | TGFβ1 |
| Invitro | Metelimumab (0.5 pg/mL-50 μg/mL) inhibits TGFβ1-stimulated IL-11 production in an A549 cell[1]. |
| Name | Metelimumab |
| CAS | 272780-74-2 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lord DM, et, al. Structure-based engineering to restore high affinity binding of an isoform-selective anti-TGFβ1 antibody. MAbs. 2018 Apr;10(3):444-452. |